Stoke Therapeutics, Inc. (STOK) Tops Q1 EPS by 182c

Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q1 EPS of $1.90, $1.82 better than the analyst estimate of $0.08. Revenue for the quarter came in at $158.57 million versus the consensus estimate of $27.66 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.

You May Also Be Interested In

• Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
• Bernstein SocGen Group Upgrades X-Fab Silicon Foundries SE (XFAB:FP) to Outperform
• Microsoft (MSFT) call put ratio 2.1 calls to 1 put as share price pulls back